Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Epidermal Growth Factor Receptor 2 (HER2) Extracellular Domain 4 is a subdomain within the extracellular region of the HER2 receptor. It is involved in receptor dimerization and activation processes. HER2 overexpression, and in particular the accessibility and confirmation of the extracellular domains, is strongly implicated in various cancers, especially breast and gastric cancers, making this domain a target for therapeutic intervention. Monoclonal antibodies, such as trastuzumab, bind near domain IV, inhibiting dimerization/activation and flagging cells for immune-mediated destruction.
Binding to the extracellular domain of HER2, inhibiting dimerization and downstream signaling
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Epidermal Growth Factor Receptor 2 Extracellular Domain 4.